Drug Profile
Influenza A virus H1N1 vaccine - EpiVax
Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator EpiVax
- Class Influenza A virus H1N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza A virus H1N1 subtype
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Influenza A virus H1N1 subtype (Prevention) in USA (Parenteral) (before September 2023) (EpiVax Pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Influenza-A-virus-H1N1-subtype(Prevention) in USA (Parenteral)
- 07 Jul 2016 Preclinical trials in Influenza-A virus H1N1 subtype (Prevention) in USA (Parenteral)